DRUG NAME: Etoposide phosphate

SYNONYM(S): Refer to etoposide monograph

COMMON TRADE NAME: ETOPOPHOS®

CLASSIFICATION: Refer to etoposide monograph

MECHANISM OF ACTION:
Refer to etoposide monograph

PHARMACOKINETICS:
Refer to etoposide monograph

USES:
Refer to etoposide monograph

SPECIAL PRECAUTIONS:
Refer to etoposide monograph
• etoposide phosphate is NOT interchangeable with other etoposide formulations and should not be substituted

SIDE EFFECTS:
Refer to etoposide monograph

Allergic reactions may be less common and severe than etoposide because etoposide phosphate does not contain polysorbate 80. Etoposide phosphate has been safely administered in patients with previous hypersensitivity,\textsuperscript{1,2} although rare cross-sensitivity has been reported.\textsuperscript{3}

INTERACTIONS:
Refer to etoposide monograph

SUPPLY AND STORAGE:

Injection:
Xediton Pharmaceuticals Inc. (for Cheplapharm Arzneimittel GmbH Germany) supplies etoposide phosphate (ETOPOPHOS®) as 100 mg single dose (preservative-free) vials of lyophilized powder. Refrigerate. Protect from light.\textsuperscript{4,6}

For basic information on the current brand used at BC Cancer, see Chemotherapy Preparation and Stability Chart in Appendix.

SOLUTION PREPARATION AND COMPATIBILITY:

For basic information on the current brand used at BC Cancer, see Chemotherapy Preparation and Stability Chart in Appendix.

Additional information:
• Etoposide phosphate is a water soluble ester of etoposide which lessens the potential for precipitation following dilution and intravenous administration.\textsuperscript{4}
Etoposide phosphate does NOT contain polysorbate 80. Therefore, diethylhexyl phthalate (DEHP) does not leach from polyvinyl chloride (PVC) containers and tubing into etoposide phosphate IV solution. Etoposide phosphate does NOT require non-DEHP containers and tubing for administration.

**PARENTERAL ADMINISTRATION:**
Refer to etoposide monograph

<table>
<thead>
<tr>
<th>Direct intravenous</th>
<th>not to be administered by direct IV route$^4$</th>
</tr>
</thead>
</table>
| Intermittent infusion | • dilute to final concentration of 0.1 mg/mL or greater$^4$  
• over 5 minutes to 3.5 hours$^4$ (e.g., over 30 minutes)$^7$  
• non-DEHP administration sets not required |

**DOSAGE GUIDELINES:**
Refer to etoposide monograph

**REFERENCES:**